1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Key Pharma News 03 AUGUST 2015

Key Pharma News 03 AUGUST 2015

  • August 2015
  • -
  • Espicom Business Intelligence
  • -
  • 38 pages

Industry Trend Analysis - Oncology Will Be Driving Force Of BMS' Revenues
Industry Trend Analysis - Hanmi Deal Underscores BI's Commitment To Core Competencies
Industry Brief - Genzyme To Acquire Caprelsa From AstraZeneca
Industry Brief - Regeneron/Sanofi Launch Major New Immuno-Oncology Collaboration
Industry Trend Analysis - Gilead Branching Out But Roots Will Continue To Grow Revenues
Industry Trend Analysis - Allergan Strengthens Mental Health Pipeline But Transformational Deal Ahead
Industry Brief - Eisai To Transfer North Carolina Plant To Biogen
Industry Brief - Baxalta Completes Oncaspar Portfolio Acquisition From Sigma-Tau
Industry Trend Analysis - M&A Activity Ahead For Biogen
Industry Trend Analysis - Actemra/RoActemra Sales Will Overtake MabThera/Rituxan In Roche's Immunology Portfolio In FY15
Industry Trend Analysis - Teva/Allergan Deal Will Reopen Mylan/Perrigo Transaction And End Actavis' Generics Business
Industry Brief - Merck Strengthens Immuno-Oncology Portfolio With cCAM Biotherapeutics Acquisition
Industry Trend Analysis - Mosquirix Sets Benchmark But Challenges Await
Industry Brief - Vibativ Approved In Canada For HABP/VABP
Industry Brief - FDA Accepts Merck's Grazoprevir/Elbasvir NDA
Industry Brief - CHMP Issues Positive Opinion On Synflorix Label Expansion
Industry Brief - Merck's Zerbaxa Gains CHMP Positive Opinion
Industry Brief - FDA Approves BMS' Daklinza For HCV GT3
Industry Brief - Janssen Submits sNDA To FDA For Olysio
Industry Brief - EMA Accepts Grazoprevir/Elbasvir MAA For Review In cHCV
Industry Brief - Teva Successfully Files MAA For Reslizumab
Industry Brief - Eisai Submits Fycompa NDA In Japan For Partial Onset/PGTC Seizures
Industry Brief - CHMP Recommends European Approval Of Praluent For Hypercholesterolaemia
Industry Brief - Keytruda Gains EU Approval For Advanced Melanoma
Industry Brief - CHMP Adopts Positive Opinion For Zalviso
Industry Brief - EC Approves Nivolumab BMS For Previously-Treated Advanced Squamous NSCLC
Industry Brief - Ono Seeks NSCLC Approval For Opdivo In Japan
Industry Brief - Final NICE Guidance Recommends BI's Vargatef
Industry Trend Analysis - Evotaz' Lack Of Competing Power Underscores Importance Of BMS' De-Diversification
Industry Trend Analysis - Resubmitted Sustol Will Be Growth Driver In CINV Drugs Market
Industry Brief - Amgen's Repatha Gains EU Approval
Industry Trend Analysis - US Biosimilar Market Tangible But Zarxio's Acceptance Will Be Challenging
Industry Brief - CHMP Recommends Approval Of Basilea's Cresemba In EU
Industry Brief - FDA Approval Sought For Arzerra As Maintenance Therapy For Relapsed CLL
Industry Brief - Tafinlar+Mekinist Gains CHMP Positive Opinion/FDA Priority Review For Advanced Melanoma
Industry Brief - EMA Validates Empliciti MAA For MM
Industry Brief - EMA Validates Two Parallel Type II Variation Applications To Extend Opdivo Indication
Industry Trend Analysis - Looming Competition Overshadows Kyprolis' Expanded Indication
Industry Trend Analysis - Limited Options Will Enable Odomzo To Take Market Share
Industry Trend Analysis - Par Will Fight To Retain Megace ES Market Share Despite Falling Sales
Industry Brief - Cresemba Phase III Study In Candida Infections Misses Primary Endpoint
Industry Brief - AstraZeneca’s Selumetinib Phase III Study In Uveal Melanoma Misses Primary Endpoint
Industry Trend Analysis - TAF To Strengthen Gilead's HIV Powerhouse Status
Industry Brief - BMS Gains FDA Breakthrough Designation For HIV-1 Attachment Inhibitor
Industry Trend Analysis - Data Keep Hopes Alive For Lilly's Solanezumab
Industry Trend Analysis - Positive Phase II Blincyto Data Will Secure Second FDA Nod
Industry Trend Analysis - Exelixis Will Finally See Success With Cabozantinib
Industry Trend Analysis - Opdivo Poised To Capitalise On Untapped RCC Market
Industry Brief - Lenvima Granted FDA Breakthrough Designation For RCC

Table Of Contents

Key Pharma News 03 AUGUST 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the ...

Cardiovascular Surgical Devices: Technologies and Global Markets

Cardiovascular Surgical Devices: Technologies and Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Learn about the trends and developments affecting each type of cardiovascular surgical technology - Analyze trends and opportunities in major regions: North America, Europe, Asia ...

TCR/CAR-T Therapies in Oncology: Analytical Tool

TCR/CAR-T Therapies in Oncology: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.